Table 1.
Examples of Pharmaceutical Company Settlements for Off-Label Promotion Under the False Claims Act 2011-2017a
| Year | Company | Drug | Settlement Amount |
|---|---|---|---|
| 2011 | UCB | Keppra | $34 million combined civil and criminal penalties |
| 2011 | Novo Nordisk | NovoSeven | $25 million |
| 2011 | Pfizer | Detrol | $14.5 million |
| 2012 | Abbott Laboratories | Depakote | $800 million |
| 2012 | Glaxo Smith Kline | Paxil, Wellbutrin, Advair, Lamictal, Zofran | $1.043 billion |
| 2012 | Amgen | Aranesp, Enbrel, Neulasta | $612 million |
| 2013 | Par Pharmaceutical | Megace ES | $22.5 million |
| 2013 | Wyeth Pharmaceuticals | Rapamune | $257.4 million |
| 2013 | Johnson & Johnson | Risperdal, Invega, Natrecor | $1.391 billion |
| 2015 | Insys Therapeutics | Subsys (opioid) | $1.1 million in Oregon, $2.9 million in New Hampshire |
| 2016 | Bristol-Myers Squibb Co | Abilify | $19.5 million |
| 2017 | Celgene | Revlimid, Thalomid | $315 million |
| 2017 | Aegerion Pharmaceuticals | Juxtapid | $28.2 million civil damages, $7.2 million criminal fine |
| 2017 | Boehringer Ingelheim Pharmaceuticals | Aggrenox, Atrovent Combivent, Micardis | $13.5 million |
a
All settlements available at the U.S. Department of Justice Office of Public Affairs website at https://www.justice.gov/opa.